Welcome to our dedicated page for Scpharmaceutical SEC filings (Ticker: SCPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings archive for scPharmaceuticals Inc. (SCPH) provides a detailed regulatory record of the company’s life as a public issuer and its eventual acquisition by MannKind Corporation. As a Nasdaq-listed company with common stock registered under Section 12(b) of the Exchange Act, scPharmaceuticals filed periodic reports and numerous current reports on Form 8-K documenting material events, financing arrangements, and strategic transactions.
For investors and researchers, key filings include annual and quarterly reports that describe product revenues from FUROSCIX, research and development spending, and selling, general and administrative expenses, along with discussions of risks and business strategy. Current reports on Form 8-K capture important milestones such as FDA approval of an expanded FUROSCIX indication for chronic kidney disease, business updates around the FUROSCIX franchise, and the company’s participation in credit facilities and revenue participation agreements.
Filings from 2025 are particularly important for understanding the change in control. A Form 8-K dated August 25, 2025 describes the Agreement and Plan of Merger with MannKind Corporation, while a Form 8-K dated October 7, 2025 details the completion of the tender offer and merger, the conversion of scPharmaceuticals shares into cash plus a non-tradable contingent value right, and the company’s status as a wholly owned subsidiary of MannKind. The same filing explains the request to Nasdaq to file a Form 25 to remove SCPH from listing and registration, and notes the intention to file a Form 15 to terminate registration and suspend reporting obligations.
The Form 25 filed on October 7, 2025 by The Nasdaq Stock Market LLC formally notifies the SEC of the removal of scPharmaceuticals’ common stock from listing and registration under Section 12(b) of the Exchange Act. Together, these documents trace SCPH’s transition from a stand-alone public company to a private subsidiary within MannKind’s corporate structure. On Stock Titan, AI-powered tools can help users quickly interpret these filings by summarizing complex language, highlighting items related to the merger, delisting, financing agreements, and other material changes that shaped scPharmaceuticals’ regulatory history.
scPharmaceuticals filed an amendment to its Schedule 14D-9 to reflect updates to a cash-and-contingent-value-rights tender offer by Seacoast Merger Sub, Inc., a MannKind subsidiary. The Offer pays $5.35 per share in cash plus one non-tradeable CVR per share that can deliver up to $1.00 in aggregate contingent cash payments if specified regulatory and net sales milestones are met by the applicable milestone outside dates. The Offer documents (Offer to Purchase and Letter of Transmittal) are attached to the Schedule TO filed September 8, 2025. This amendment also lists an Unsecured Promissory Note dated September 23, 2025 between Parent and the Company as an exhibit.
scPharmaceuticals filed an amendment to its Schedule 14D-9 regarding the tender offer by a MannKind subsidiary to acquire all outstanding shares for $5.35 per share in cash plus one contingent value right (CVR) per share that may pay up to $1.00 upon achievement of specified regulatory and net sales milestones. The amendment replaces two paragraphs under "Regulatory Approvals" in Item 8 of the Schedule 14D-9 and notes the Company received thirteen demand letters alleging disclosure deficiencies and one Section 220 books-and-records demand. The Company states it believes those claims are without merit. The amendment is signed by the CEO on September 22, 2025.
Glazer Capital, LLC and its Managing Member Paul J. Glazer filed a Schedule 13G reporting shared beneficial ownership of 2,474,820 shares of scPharmaceuticals Inc. common stock, representing 4.64% of the class. The filing notes the shares are held by funds and managed accounts for which Glazer Capital serves as investment manager and that the Reporting Persons do not assert sole voting or dispositive power over these shares. The statement also indicates that the Reporting Persons have ceased to be beneficial owners of more than 5% of the class.
scPharmaceuticals received a tender offer from Seacoast Merger Sub, a MannKind subsidiary, to acquire all outstanding shares for $5.35 per share in cash plus one contingent value right (CVR) per share that can pay up to $1.00 in aggregate upon achievement of specified regulatory and net-sales milestones. The Offer and related Letter of Transmittal were filed on the Schedule TO on September 8, 2025. Under the agreed terms the aggregate consideration could be up to $6.35 per share, which the filing says implied approximately a 43% premium to the August 20, 2025 closing price of $4.45. The record summarizes prior indications and competing non-binding proposals, milestone payment schedules tied to SCP-111 FDA approval windows and trailing 12-month net sales, potential impacts from a Device Supplier pricing increase, and customary pre-closing covenants and severance arrangements for executives. The filing also notes HSR/antitrust waiting periods and that the Offer is subject to the conditions specified in the Schedule TO.
The communication states that scPharmaceuticals has initiated a tender offer process and that a Schedule 14D-9 will be filed with the SEC. The offer to purchase scPharmaceuticals common stock will be made only through the formal offer documents filed as part of the Schedule TO, including the offer to purchase and letter of transmittal, and investors are urged to read the tender offer statement and any solicitation/recommendation statement when available. It warns that forward-looking statements involve risks, including integration risks from acquisitions, development and clinical trial timing risks, uncertain milestone payments tied to a contingent value right, and potential adverse effects on Parent's share price if expected benefits are not realized. The filing points readers to www.sec.gov and scPharmaceuticals' Investor Relations page for free copies of related documents.
scPharmaceuticals Inc. has disclosed that it entered into an Agreement and Plan of Merger dated
scPharmaceuticals and Parent plan filings related to a proposed tender offer: a Schedule 14D-9 will be filed by scPharmaceuticals and the offer will be made only via the Offer to Purchase, Letter of Transmittal and related Schedule TO documents. Investors are urged to read the tender offer statement and the solicitation/recommendation statement when available because they will contain important terms and conditions for tendering shares. Free copies of those statements will be available on the SEC website and via the Offer Information Agent, and scPharmaceuticals will post related filings in its Investor Relations section. The communication discloses customary transaction risks, including integration risk, development and clinical timing risks, uncertainty around contingent value right milestone payments, and the possibility that Parents share price could decline if perceived benefits are not realized. Exhibits include internal emails and a LinkedIn announcement dated August 25, 2025.
scPharmaceuticals (SCPH) entered a definitive merger transaction with MannKind Corporation and its merger subsidiary, accompanied by a related press release. The merger agreement dated August 24, 2025, provides that in-the-money Company Options outstanding immediately before the effective time will be cancelled and converted into a cash payment equal to the excess of the cash merger consideration over each option's exercise price plus one contingent value right (CVR) per underlying share. The CVRs will be nontransferable except for limited exceptions and a register of CVR holders will be maintained. The filing includes typical deal protections restricting the Company from soliciting or recommending alternative acquisition proposals, subject to board fiduciary duties. The document references SEC filings and risk factor disclosures.
scPharmaceuticals Inc. filed an 8-K reporting an amendment to a supply agreement: Amendment 1 to the Supply Agreement dated August 20, 2025 between West Pharmaceutical Services, Inc. and the registrant. The filing includes a cover page interactive data file embedded in the inline XBRL document and is signed by John H. Tucker, President and Chief Executive Officer of scPharmaceuticals Inc.
The filing identifies the amendment document and the parties but does not provide the amendment's financial terms, operational changes, or material effects on the company within the provided excerpt.